Literature DB >> 29196879

The feasibility of physiologically based pharmacokinetic modeling in forensic medicine illustrated by the example of morphine.

Nadine Schaefer1, Daniel Moj2, Thorsten Lehr2, Peter H Schmidt3, Frank Ramsthaler3.   

Abstract

In forensic medicine, expert opinion is often required concerning dose and time of intake of a substance, especially in the context of fatal intoxications. In the present case, a 98-year-old man died 4 days after admission to a hospital due to a femur neck fracture following a domestic fall in his retirement home. As he had obtained high morphine doses in the context of palliative therapy and a confusion of his supplemental magnesium tablets with a diuretic by the care retirement home was suspected by the relatives, a comprehensive postmortem examination was performed. Forensic toxicological GC- and LC-MS analyses revealed, besides propofol, ketamine, and a metamizole metabolite in blood and urine, toxic blood morphine concentrations of approximately 3 mg/l in femoral and 5 mg/l in heart blood as well as 2, 7, and 10 mg/kg morphine in brain, liver, and lung, respectively. A physiologically based pharmacokinetic (PBPK) model was developed and applied to examine whether the morphine concentrations were (i) in agreement with the morphine doses documented in the clinical records or (ii) due to an excessive morphine administration. PBPK model simulations argue against an overdosing of morphine. The immediate cause of death was respiratory and cardiovascular failure due to pneumonia following a fall, femur neck fracture, and immobilization accompanied by a high and probably toxic concentration of morphine, attributable to the administration under palliative care conditions. The presented case indicates that PBPK modeling can be a useful tool in forensic medicine, especially in question of a possible drug overdosing.

Entities:  

Keywords:  Forensic medicine; Morphine; Palliative care; Physiologically based pharmacokinetic modeling

Mesh:

Substances:

Year:  2017        PMID: 29196879     DOI: 10.1007/s00414-017-1754-8

Source DB:  PubMed          Journal:  Int J Legal Med        ISSN: 0937-9827            Impact factor:   2.686


  53 in total

1.  Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: extension to describe performance of solid dosage forms.

Authors:  Kirstin Thelen; Katrin Coboeken; Stefan Willmann; Jennifer B Dressman; Jörg Lippert
Journal:  J Pharm Sci       Date:  2011-11-28       Impact factor: 3.534

2.  Estimation of the Time Interval between the Administration of Heroin and the Sampling of Blood in Chronic Inhalers.

Authors:  Nathalie Dubois; Claude Hallet; Laurence Seidel; Isabelle Demaret; David Luppens; Marc Ansseau; Eric Rozet; Adelin Albert; Philippe Hubert; Corinne Charlier
Journal:  J Anal Toxicol       Date:  2015-02-03       Impact factor: 3.367

Review 3.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

4.  Prediction of Clearance in Neonates and Infants (≤ 3 Months of Age) for Drugs That Are Glucuronidated: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling.

Authors:  Iftekhar Mahmood; Tasneem Ahmad; Najia Mansoor; S M Sharib
Journal:  J Clin Pharmacol       Date:  2016-11-08       Impact factor: 3.126

5.  Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7.

Authors:  Andrew N Stone; Peter I Mackenzie; Aleksandra Galetin; J Brian Houston; John O Miners
Journal:  Drug Metab Dispos       Date:  2003-09       Impact factor: 3.922

6.  Plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide after intravenous and oral administration to healthy volunteers: relationship to nonanalgesic actions.

Authors:  D Westerling; C Persson; P Höglund
Journal:  Ther Drug Monit       Date:  1995-06       Impact factor: 3.681

7.  Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs.

Authors:  Stefan Willmann; Karsten Höhn; Andrea Edginton; Michael Sevestre; Juri Solodenko; Wolfgang Weiss; Jörg Lippert; Walter Schmitt
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-03-13       Impact factor: 2.410

8.  Development of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in Pregnancy.

Authors:  Saeed Alqahtani; Amal Kaddoumi
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

9.  Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.

Authors:  Jan-Frederik Schlender; Michaela Meyer; Kirstin Thelen; Markus Krauss; Stefan Willmann; Thomas Eissing; Ulrich Jaehde
Journal:  Clin Pharmacokinet       Date:  2016-12       Impact factor: 6.447

10.  Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.

Authors:  Stefan Willmann; Corina Becker; Rolf Burghaus; Katrin Coboeken; Andrea Edginton; Jörg Lippert; Hans-Ulrich Siegmund; Kirstin Thelen; Wolfgang Mück
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

View more
  2 in total

1.  PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small Infants.

Authors:  Chie Emoto; Trevor N Johnson; Sibylle Neuhoff; David Hahn; Alexander A Vinks; Tsuyoshi Fukuda
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-06-19

2.  Data Digitizing: Accurate and Precise Data Extraction for Quantitative Systems Pharmacology and Physiologically-Based Pharmacokinetic Modeling.

Authors:  Jan-Georg Wojtyniak; Hannah Britz; Dominik Selzer; Matthias Schwab; Thorsten Lehr
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-06-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.